Sanofi

Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

Hand holding a liquid sample, preparing for mass spectrometry analysis

Second Quarter 2026 Results

Second quarter 2026 results were reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation was followed by a Q&A session.

Press Releases


September 22, 2026
An Open Letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi

September 14, 2026
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

August 4, 2026
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Upcoming Events

28Sep

2026

Santander Virtual Pharma Day – virtual

Conferences


30Oct

2026

Third quarter 2026 results

Third quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on October 30, 2026. The presentation will be followed by a Q&A session.

12:30 - 13:30 CET (7:30am - 8:30am EDT)

Quarterly results


28Apr

2027

Annual General Meeting 2027

The Sanofi General Meeting will be held on April 28, 2027.

Annual general meetings


Female scientist in white lab coat and safety equipment working with a tablet at a laboratory workstation with protective hood
Shuang Yang, Scientist, China

2025 20-F

Presenting our 2025 FORM 20-F.

Sanofi's dividends until 2025

Dividend (in euros) per share

31st Consecutive Year of Dividend Increase ​

Sanofi's dividends until 2025

Dividend (in dollars) per ADR (½ share)

Dr. Yohana Mokiwa has a serious expression, blue shirt and stethoscope, as he speaks with a patient in a pop up clinic
Dr. Yohana Mokiwa speaking with a patient in a pop-up clinic, Dar es Salaam, Tanzania

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00